Last €3.19 EUR
Change Today +0.14 / 4.59%
Volume 386.6K
ALNEV On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
As of 7:36 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

neovacs (ALNEV) Snapshot

Open
€3.09
Previous Close
€3.05
Day High
€3.28
Day Low
€3.05
52 Week High
02/25/14 - €4.40
52 Week Low
11/29/13 - €1.66
Market Cap
62.7M
Average Volume 10 Days
645.1K
EPS TTM
€-0.35
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOVACS (ALNEV)

Related News

No related news articles were found.

neovacs (ALNEV) Related Businessweek News

No Related Businessweek News Found

neovacs (ALNEV) Details

Neovacs S.A., a biotechnology company, focuses on active immunotherapy for autoimmune and inflammatory diseases in France. The company’s product pipeline comprises tumor necrosis factor kinoid for the treatment of rheumatoid arthritis and Crohn’s diseases; interferon a-kinoid to treat lupus; and vascular endothelial growth factor kinoid for the treatment of macular degeneration and cancer. Neovacs S.A. is based in Paris, France.

17 Employees
Last Reported Date: 09/26/14

neovacs (ALNEV) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: €34.9K
Compensation as of Fiscal Year 2013.

neovacs (ALNEV) Key Developments

Neovacs Signs Financing Project with Kepler Cheuvreux

NEOVACS announced the signing of a financing project with Kepler Cheuvreux. Neovacs has an innovative portfolio of vaccines in clinical and pre-clinical stage, which will need several years to develop until registration. Some of these products should be subject of a licensing or co-development agreement, assuring, thus a long lasting scientific partnership as well as the co-financing of common projects. In addition and in order to accompany its plan of development, Neovacs has already been able to agree with Kepler Cheuvreux on a financing tool, covering several years, including optional items, in order to be able to raise funds according to the evolution of the company's financial needs.

Neovacs S.A. Presents at EPIC Biotech 2014, Oct-02-2014 03:00 PM

Neovacs S.A. Presents at EPIC Biotech 2014, Oct-02-2014 03:00 PM. Venue: The King's Fund, 11-13 Cavendish Square, London, W1G 0AN, United Kingdom.

Neovacs S.A. Reports Earnings Results for the Six Months Ended June 30, 2014

Neovacs S.A. reported earnings results for the six months ended June 30, 2014. For the period, the company reported revenues of €55,000 against €10,000 a year ago. Operating loss was €4,518,000 against €3,646,000 a year ago. Pretax loss was €4,582,000 against €3,683,000 a year ago. Net loss was €3,861,000 against €3,279,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNEV:FP €3.19 EUR +0.14

ALNEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNEV.
View Industry Companies
 

Industry Analysis

ALNEV

Industry Average

Valuation ALNEV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 675.1x
Price/Book 21.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 594.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVACS, please visit www.neovacs.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.